



2021

ANNUAL REPORT

MESSAGE FROM THE EXECUTIVE DIRECTOR

Dear friends of HCS,

As we enter this new year after enduring yet another extraordinarily challenging one, I cannot help but feel hopeful. Together we have overcome seemingly insurmountable obstacles over the last few years. And, although many of our dreams were deferred since the start of the COVID-19 pandemic, we have many successes to celebrate.

HCS continued to provide support for all dialysis beneficiaries at both hemodialysis centers despite the country's worsening financial crisis. Dialysis sessions, blood tests, and even PCR testing for COVID-19 are offered free of charge. In 2022 we are looking forward to moving our hemodialysis center in Beddawi refugee camp to a dedicated space in the newly constructed Safad Hospital. This will allow us to accommodate more patients simultaneously in a brand-new state-of-the-art hemodialysis unit.

Our thalassemia and sickle cell disease beneficiaries are slowly returning to the hematology clinic at the American University of Beirut Medical Center after many months of delays related to the pandemic. There, they are assessed by a world-class medical team and referred for any necessary blood tests or imaging, all of which are covered by HCS. A small but important victory was the recently secured donation of 200 boxes of hydroxyurea, a medication that is essential to keeping our sickle cell beneficiaries healthy.

With the value of the Lebanese lira falling against the dollar, HCS faced some challenges in its project to support patients' surgeries and hospitalizations. Despite this, HCS supported more beneficiaries in 2021 than in the year prior. In 2022, we will continue to work our hardest to find solutions to each new challenge we face. As my first month at HCS comes to a close, I am optimistic that we will persevere and grow despite the complex challenges we face in Lebanon. Collective action towards a common objective has the power to conquer even the biggest of barriers. Together we can alleviate the suffering of our Palestinian brothers and sisters.

Best regards,

Hebah El-Rayess MD, MPH
Executive Director

BOARD OF DIRECTORS

DR. WALID ALAMI

President

DR. MONA OSMAN

Member

MRS. WAFA AL YASSIR

Vice President

DR. MARWAN AKEL

Member

MR. KASSEM AINA

Treasurer

DR. MARWAN REFAAT

Member

MRS. HIBA MAWED

Secretary

STAFF MEMBERS

DR. HEBAH EL RAYESS

Executive Director

MR. MOHAMMED EL SADEK

Accountant

MOHAMMED ABO ISSA

Social Worker

YUSSEF ABDULATIF

Social Worker

TABLE OF CONTENT

04

HIGHLIGHT OF
ACHIEVEMENTS

05

HEMODIALYSIS
PROJECT

06

THALASSEMIA AND
SICKLE CELL DISEASE
PROJECT

07

SURGERY AND
HOSPITALIZATION
PROJECT

09

MEDICAL IN-KIND
DONATION PROJECT
(MIKP)

10

FINANCIAL
HIGHLIGHTS



OUR MISSION

HCS mission is to provide health security to the Palestinian refugees in Lebanon.



OUR VALUES

HCS ethical framework is grounded in the following values: commitment, solidarity, dignity and tolerance.



OUR OBJECTIVES

Contribute towards costs of secondary and tertiary medical care for Palestinian refugees while ensuring quality care.

Support emergency cases that are not covered by any other institution.

Supporting chronic disease patients such as kidney failure and blood diseases.

Engage in evidence-based advocacy to promote high quality and more dignified health care of Palestinian refugee.

Provide health awareness.

Provide medications and medical supplies according to needs.

HIGHLIGHT OF ACHIEVEMENTS

AS OF DECEMBER 31 2021

TOTAL
BENEFICIARIES

469

SURGERY
PROJECT

191

THALASSEMIA
& S.C. DISEASE
PROJECT

114

KIDNEY
DIALYSIS
PROJECT


164

HAMSHARI
DIALYSIS
SESSIONS

12,518


SAFAD
DIALYSIS
SESSIONS

5,149



% INCREASE IN THALASSEMIA
& S.C. DISEASE BENEFICIARIES
COMPARED TO 2020

% INCREASE IN SURGERY BENEFICIARIES
COMPARED TO 2020



HEMODIALYSIS PROJECT

RELIABLE CARE

2021 was an extremely busy year at our two hemodialysis units. Thanks to our main donors, Taawon and NORWAC, HCS was able to support one-hundred and sixty-four beneficiaries with kidney failure requiring dialysis. At Hamashari Hospital, one-hundred and twenty patients underwent more than twelve-thousand five hundred dialysis sessions in 2021. At Safad Hospital, forty-four beneficiaries received 5,149 sessions of hemodialysis.



Location	No. of Beneficiaries	Dialysis Sessions per Year	Average Age
Hamshari Center	120	12,518	48
Safad Hospital	44	5,149	45

NEW BEGINNINGS

The hemodialysis unit at Hamshari Hospital received a much-needed makeover, including a new water treatment system and new dialysis chairs thanks to a grant from United Palestinian Appeal. Additionally, our partner, the Palestinian Red Crescent, is ready to open a new kidney dialysis unit in the newly built Safad Hospital located in Beddawi refugee camp.



PAINTING OF HAMSHARI HOSPITAL HEMODIALYSIS CENTER



INSTALLATION OF A NEW WATER TREATMENT SYSTEM AT HAMSHARI HOSPITAL HEMODIALYSIS CENTER

THALASSEMIA & SICKLE CELL DISEASE PROJECT

THALASSEMIA &
SICKLE CELL DISEASE
PROJECT BENEFICIARIES

114



PATIENTS BENEFITS
FROM THE PROJECT

CIRCULAR EXAMINATIONS AT **AUBMC**
MEDICATION SUPPORT (**HYDROXYUREA**)
EMERGENCIES (**TESTS & SURGERIES**)

A LIFETIME OF SUPPORT

This project seeks to meet the needs of Palestinian refugees with thalassemia and sickle cell disease. Thanks to our donors, NORWAC and PCRF, we are able to support our 114 beneficiaries from childhood into adulthood. HCS accomplishes this by providing our beneficiaries with access to the highest quality medical care. Regular visits with our partner hematologist at the American University of Beirut, Dr. Miguel Abboud, are key. During their clinic visits, beneficiaries learn how to manage their diseases in order to minimize complications. Blood tests, ultrasounds, MRIs, EKGs, x-rays, and vaccinations are performed when needed.



YASSER RECEIVING BLOOD TRANSFUSION

SURGERIES & HOSPITALIZATION PROJECT

TOGETHER IN DIFFICULT TIMES

Surgeries and hospitalizations can be a significant source of mental, physical, and financial stress for anyone. The lack of healthcare coverage intensifies this stress for Palestinian refugees in Lebanon. The objective of this project is to help ease the financial burden associated with surgeries and hospitalizations. Whether the surgery or hospitalization is emergent or planned, HCS covers part of the cost up to \$2,500 as long as the total cost is more than 6,000,000 Lebanese pounds.

SURGERY TYPE	0-16	17-27	28-40	41-59	60+	TOTAL
PT + STENT	2	0	3	17	22	44
ORTHOPEDIC	7	4	4	11	14	40
GENERAL SURGERY	9	5	8	7	4	33
OPEN HEART	2	0	1	7	17	27
CANCER	2	0	3	4	8	17
OCULAR SURGERY	7	1	0	2	2	12
OTHER MEDICAL SUPPORT (ICU)	3	1	0	3	11	18
TOTAL	32	11	19	51	78	191

SUCCESS STORY

Alma Yahya AL Saleh was born prematurely at 8 months of gestation on the 5th of November 2021. She spent 40 days in the Neonatal Intensive Care Unit (NICU). HCS helped cover a significant proportion of the hospital bill (\$2500 at 3900LBP about 40% of the total cost). Upon follow-up Alma was found to be a healthy, happy, newborn baby.



IN THE NICU



1 WEEK AFTER LEAVING THE HOSPITAL

SURGERY TYPE

	TOTAL	MALE	FEMALE
PT + STENT	44	28	16
ORTHOPEDIC	40	20	20
GENERAL SURGERY	33	19	14
OPEN HEART	27	15	12
CANCER	17	9	8
OCULAR SURGERY	12	7	5
OTHER MEDICAL SUPPORT (ICU)	18	12	6
TOTAL	191	110	81



MEDICAL IN-KIND DONATION PROGRAM (MIKP)

SECURING THE ESSENTIALS

The HCS' MIKP was created to fulfill a need in the Palestinian refugee population for essential medications that are either unaffordable or difficult to find. HCS works in collaboration with Al Shifaa hospital, Beit Atfal Al Summoud, the Palestinian Red Crescent Society, Dar Al Ajaza, and the YMCA to distribute the medications.

ANERA has served as the main donor to the program since its inception in 2004. In 2021, ANERA provided 3 shipments of medications to HCS beneficiaries, including over 1,000 boxes of antibiotics and 2,400 boxes of medication for the treatment of diabetes. HCS also received its third donation of hydroxyurea from Hikma Pharmaceuticals. This medication is essential to our beneficiaries with sickle cell disease. UPA played an important role in 2021 by securing prenatal vitamins that were otherwise unavailable in Lebanon.



DIALYSIS CHAIRS RECEIVED FROM UPA AT HAMSHARI



SHIPMENT OF 200 BOXES OF HYDROXYUREA FROM HIKMA PHARMACEUTICALS



ISRAA RECEIVING HYDROXYUREA

FINANCIAL HIGHLIGHTS

Statement of Financial Position for the Year Ended December 31, 2021

	Amount 2021 (USD)
ASSETS	
Cash At Bank	426,081.14
Account Recievable	417,381.30
Automobile/Vehicles (Net)	1.00
Total Assets	843,463.44
LIABILITIES & FUND BALANCE	
Current Liabilities	
Kidney Dialysis centers (suppliers)	71,027.34
Hospital Bills	48,055.35
HCS Salaries	1,686.00
PRCS Salaries	5,350.00
Promissory Note	94,428.00
Deferred Revenue (Taawon)	160,005.00
Total Current Liabilities	380,551.69
Fund Balance at the beginning of the year	318,087.84
Surplus for the period	144,823.91
Ending Fund balance	462,911.75
Total Liabilities & Fund balance	843,463.44


**Statement of Activities
for the Year Ended December 31, 2021**

	Amount 2021 (USD)
REVENUE, GAINS, & OTHER SUPPORTS	
Welfare Association	1,011,652.00
Norwac	97,000.00
United Palestinian Appeal	45,000.00
Basheer Alami family fund	50,000.00
Palestine Children Relief Fund	29,548.91
Individuals Donations	21,984.00
NGO's Staff Contributions	3,448.78
Other Income (Interest & gain on currency exchange)	17,676.60
TOTAL REVENUE, GAINS, & OTHER SUPPORTS	1,276,310.29
EXPENSES	
Program service	
Hospitalizations and medical Support	298,909.90
Promissory Note (not paid Yet)	85,000.00
Thalassemia & Sickle cell Treatment	35,962.37
Kidney Dialysis Center- Hamshari & Safad Hospital	534,118.68
Hygiene Supplies for Covid- 19 for kidney Dialysis centers	22,192.00
Medical Equipment & Rehabilitation for Hamshari Dialysis	52,789.40
Total Program service	1,028,972.35
Administrative and Support	
Employees' Salaries	77,375.00
Auditing	3,000.00
Office equipment/ Supplies/ printing & Stationary	1,789.66
Employees medical Insurance	11,391.00
Office rental – services & Generator Fees	2,053.03
Transportation- parking & Automobile Maintenance	1,080.23
Bank service Charges	2,516.44
Miscellaneous/ Utilities/Maintenance/telephone bills	3,308.67
Total Administrative and Support	102,514.03
TOTAL EXPENSES	1,131,486.38
YEAR END BALANCE SURPLUS	144,823.91

Statement of Cash Flows
for the Year Ended December 31, 2021

	Amount 2021 (USD)
CASH FLOWS FROM OPERATING ACTIVITIES	
Cash received from Welfare association	757,715.30
Cash received from NORWAC	97,000.00
Cash received from United Palestinian Appeal	45,000.00
Cash received from Basheer Alami Family Fund	50,000.00
Cash received from Individuals Donations	21,984.00
Cash received from Palestine Children relief Fund	29,548.91
Cash received from Contributions from NGO's Staff	5,167.60
Cash received from Other Income	17,676.60
Cash paid to Hospitalization Support	(273,424.57)
Cash paid for medical Aid from Previous year	(16,036.00)
Hygiene Supplies for Covid- 19 for kidney Dialysis centers	(22,192.00)
Cash paid for Thalassemia & Sickle cell Treatment	(35,962.37)
Cash paid For Kidney Dialysis Center-hamshari & Safad	(437,224.65)
Cash paid for Medical Equiment & Rehabilitation of Hamshari Dialysis Center	(52,789.40)
Administrative Expenses	(104,053.03)
Net Increase in cash	82,410.39
Cash and Cash equivalents at beginning of year	343,670.75
Cash and Cash equivalents at end of year	426,081.14

SPECIAL THANKS TO OUR DONORS AND PARTNERS



التعاون
Taawon



NORWAC
NORWEGIAN AID COMMITTEE

UPA

United Palestinian Appeal



PCRf 
Palestine Children's Relief Fund

